Seroprevalence of Hepatitis A Virus in Pediatric Patients with Hematologic Malignancies after Chemotherapy and Hematopoietic Cell Transplantation

Ja Un Moon; A Luem Han; Eui Soo Lee; Seong Koo Kim; Seung Beom Han; Jae Wook Lee; Nack Gyun Chung; Bin Cho; Dae Chul Jeong; Jin Han Kang

doi:10.3947/ic.2019.51.2.183

Seroprevalence of Hepatitis A Virus in Pediatric Patients with Hematologic Malignancies after Chemotherapy and Hematopoietic Cell Transplantation

Infect Chemother. 2019 Jun;51(2):183-187. doi: 10.3947/ic.2019.51.2.183.

Authors

Ja Un Moon¹, A Luem Han¹, Eui Soo Lee¹, Seong Koo Kim^{1

2}, Seung Beom Han^{1

3}, Jae Wook Lee^{1

2}, Nack Gyun Chung^{1

2}, Bin Cho^{1

2}, Dae Chul Jeong^{1

4}, Jin Han Kang^{1

4}

Affiliations

¹ Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea.
² Catholic Hematology Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
³ The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea. beomsid@catholic.ac.kr.
⁴ The Vaccine Bio Research Institute, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Abstract

This retrospective study was performed to determine the seroprevalence of hepatitis A virus (HAV) in children and adolescents with hematologic malignancies after the completion of chemotherapy and hematopoietic cell transplantation (HCT). Of 97 enrolled patients, 60 (61.9%) were seropositive for HAV. The seroprevalences in patients undergoing chemotherapy and HCT were 60.3% (41/68) and 65.5% (19/29), respectively (P = 0.628). No significant factors associated with seropositivity for HAV after chemotherapy and HCT were identified. Anti-HAV tests and HAV re-vaccinations can be considered in children and adolescents with underlying hematologic malignancies after chemotherapy and HCT based on the anti-HAV results.

Keywords: Chemotherapy; Child; Hepatitis A virus; Seroprevalence; Stem cell transplantation.